JP2009535021A5 - - Google Patents

Download PDF

Info

Publication number
JP2009535021A5
JP2009535021A5 JP2009506889A JP2009506889A JP2009535021A5 JP 2009535021 A5 JP2009535021 A5 JP 2009535021A5 JP 2009506889 A JP2009506889 A JP 2009506889A JP 2009506889 A JP2009506889 A JP 2009506889A JP 2009535021 A5 JP2009535021 A5 JP 2009535021A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
identity
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009506889A
Other languages
English (en)
Japanese (ja)
Other versions
JP5431920B2 (ja
JP2009535021A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CH2007/000202 external-priority patent/WO2007124610A1/en
Publication of JP2009535021A publication Critical patent/JP2009535021A/ja
Publication of JP2009535021A5 publication Critical patent/JP2009535021A5/ja
Application granted granted Critical
Publication of JP5431920B2 publication Critical patent/JP5431920B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009506889A 2006-04-28 2007-04-27 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体 Expired - Fee Related JP5431920B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
US60/795,831 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013112192A Division JP5911821B2 (ja) 2006-04-28 2013-05-28 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体

Publications (3)

Publication Number Publication Date
JP2009535021A JP2009535021A (ja) 2009-10-01
JP2009535021A5 true JP2009535021A5 (enExample) 2011-07-28
JP5431920B2 JP5431920B2 (ja) 2014-03-05

Family

ID=38515389

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009506889A Expired - Fee Related JP5431920B2 (ja) 2006-04-28 2007-04-27 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体
JP2013112192A Active JP5911821B2 (ja) 2006-04-28 2013-05-28 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013112192A Active JP5911821B2 (ja) 2006-04-28 2013-05-28 受容体チロシンキナーゼalkの細胞外ドメインに結合する抗体

Country Status (16)

Country Link
US (3) US7902340B2 (enExample)
EP (2) EP2604627A1 (enExample)
JP (2) JP5431920B2 (enExample)
KR (1) KR101457228B1 (enExample)
CN (1) CN101443361B (enExample)
AU (1) AU2007246144B2 (enExample)
BR (1) BRPI0710971A2 (enExample)
CA (1) CA2650822C (enExample)
DK (1) DK2013236T3 (enExample)
ES (1) ES2547248T3 (enExample)
IL (1) IL194752A0 (enExample)
MX (1) MX2008013705A (enExample)
NZ (1) NZ572248A (enExample)
PL (1) PL2013236T3 (enExample)
RU (1) RU2460540C2 (enExample)
WO (1) WO2007124610A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007246144B2 (en) * 2006-04-28 2012-12-06 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
MX345395B (es) 2008-06-25 2017-01-30 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
WO2009155723A2 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムFc二重特異性抗体
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
WO2015184231A2 (en) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
EP3341021A4 (en) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
JP7017015B2 (ja) 2015-10-13 2022-02-08 エウレカ セラピューティクス インコーポレイテッド ヒトcd19に特異的な抗体剤及びその使用
RU2767209C2 (ru) 2015-10-23 2022-03-16 Еурека Терапьютикс, Инк. Химерные конструкции антитело/т-клеточный рецептор и их применения
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
IL310182A (en) 2017-04-26 2024-03-01 Eureka Therapeutics Inc ׂ A Delaware Corp Structures of chimeric antibody/T-cell receptor and uses thereof
EP3749682B1 (en) * 2018-02-09 2025-09-24 Acceleron Pharma Inc. Treating heterotopic ossification
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
EP0938506B1 (en) 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
DE60141518D1 (de) * 2000-06-14 2010-04-22 Univ Georgetown Pleiotrophin wachstumfaktor rezeptor alk zur behandlung von proliferativen, gefässer- und neurologischen erkrankungen
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
CN105175535A (zh) 2002-05-22 2015-12-23 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
AU2007246144B2 (en) * 2006-04-28 2012-12-06 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Similar Documents

Publication Publication Date Title
JP2009535021A5 (enExample)
TWI713942B (zh) 與集落刺激因子1受體(csf1r)結合之抗體類
RU2008146922A (ru) Антитела, связывающиеся с внеклеточным доменом тирозинкиназного рецептора (alk)
JP2010535012A5 (enExample)
JP6681433B2 (ja) P2x7受容体アンタゴニスト及びアゴニスト
JP2020501531A5 (enExample)
CN108473563B (zh) 改进的tnf结合剂
JP2010511388A5 (enExample)
JP2011046732A5 (enExample)
JP2016507523A5 (enExample)
JP2019526273A5 (enExample)
JP2019522490A5 (enExample)
JP2017526339A5 (enExample)
JP2012530496A5 (enExample)
JP2011509245A5 (enExample)
PE20141564A1 (es) Moleculas de union para bcma y cd3
JP2013519364A5 (enExample)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2014526898A5 (enExample)
JP2016538830A5 (enExample)
JPWO2021139777A5 (enExample)
JP2020502271A5 (enExample)
HRP20150439T1 (hr) Protutijela za humani angiopoietin 2
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2017533694A5 (enExample)